US Trustee Flags Ch. 11 Sale Restrictions In Bid For Aegerion
The federal bankruptcy watchdog cried foul on Thursday about Amryt Pharma PLC's $400 million bid for embattled specialty drug company Aegerion, saying overly restrictive rules proposed by the pair could prevent...To view the full article, register now.
Already a subscriber? Click here to view full article